kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human MAP kinase 12 / p38 gamma, active, 10 µg  

Recombinant human MAP kinase 12 / p38 gamma, active, 10 µg

Recombinant human mitogen-activated protein kinase 12 / p38 gamma / SAPK3, active enzyme

Alternate names: recombinant human p38 protein kinase, SAPK3, Stress-activated protein kinase 3, MAPK12, mitogen-activated protein kinase 12, p38 γ kinase

More details


Availability: within 3 days

295,00 €

Background: The p38 MAPK (mitogen-activated protein kinase) pathway contains protein kinases which engage in respond to various extracellular stimuli an intracellular signalling cascade coordinating the activation of gene transcription, protein synthesis, cell cycle machinery, cell death, and differentiation. The different p38 MAPK family members (p38α, p38β, p38γ, p38δ encoded by different genes show an approximately 60% identical in their amino acid sequence but have different tissue expression patterns. p38 MAPKs being activated by dual phosphorylation of the Thr-Gly-Tyr in the activation loop sequence by MKKs/MAP2Ks (MKK6 and MKK3). Down-regulation of p38 MAPK is achieved for instance by Wip1, a phosphatase of the PP2C family that can be transcriptionally up-regulated by p53 or by MKPs, a family of dual-specificity protein phosphatases. Upon activation p38 MAP kinases can phosphorylate substrates on Ser-Pro or Thr-Pro motifs on MSK1 and 2, which directly phosphorylate the transcription factors CREB, ATF1, or cytosolic proteins such as phospholipase A2, Bcl-2 family proteins and cyclins. Because of the important role of p38α in inflammatory diseases such as psoriasis or arthritis it is also an interesting pharmaceutical target. Based on SB203580, one of the first discovered p38α inhibitors structurally diverse p38α and p38β inhibitors have been developed with both enhanced potency and specificity.

Human p38g/SAPK3gamma, recombinantly expressed in E. coli., full lenght protein, untagged, activated with MKK6 SDTD

Theoretical MW : 43.3 kDa
Expression system: E.coli
Purification: Immobilized metal affinity chromatography (IMAC)
Storage buffer: 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT, 20% glycerol
Purity: >95 %
Protein concentration: 0.4 mg/ml (Bradford method using BSA as standard protein)
Method for determination of Km value & specific activity: luminescent ADP detection assay, ADP Glo
Specific activity: 160,000 pmol/mg×min

Entrez Gene ID: 6300
UniProtKB: P53778

Ordering information: shipped on dry ice


Use the p38 MAPK - SPR Binding Assay of BIAFFIN for comprehensive kinetic characterization of your small molecule kinase inhibitors. 


Figure: Real-time kinetic analysis of kinase inhibitor SB203580 binding to p38α using surface plasmon resonance.

We provide our Kinascreen services to kinetically characterize small molecule kinase inhibitors for all p38 isoforms (p38α, p38β, p38γ and p38δ) in their phosphorylated (activated) and unphosphorylated (non-activated) state. 

Please contact our application specialists to obtain more information and an individual quote tailored to your specific needs. 

Product specific literature references:

Cuadrado A, Nebreda AR.  (2010) “Mechanisms and functions of p38 MAPK signalling.” Biochem J. 1;429(3):403-17.

Kyriakis JM, Avruch J. (2001) „Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.“ Physiol Rev.81(2):807-69.

Roux PP, Blenis J.,(2004) “ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.” Microbiol Mol Biol Rev. 68(2):320-44.

Shin J, Park B, Ahn K eta al. (2004) "Promyelocytic leukemia is a direct inhibitor of SAPK2/p38 mitogen-activated protein kinase" J Biol Chem. 279(39):40994-1003

Saklatvala J (2004) "The p38 MAP kinase pathway as a therapeutic target in inflammatory disease" Curr Opin Pharmacol. 4(4):372-7

The following products could also be interesting for you: